You are here

Clinical Trials: Cord Blood

Condition:   Alzheimer's Disease
Interventions:   Biological: human umbilical cord blood derived mesenchymal stem cells;   Other: Normal saline 2mL
Sponsor:   Medipost Co Ltd.
Recruiting - verified April 2017
Condition:   Sensorineural Hearing Loss
Intervention:   Genetic: Autologous Stem Cells
Sponsors:   James Baumgartner, MD;   CBR Systems, Inc.
Condition:   Type 1 Diabetes
Intervention:   Device: Stem Cell Educator
Sponsors:   Tianhe Stem Cell Biotechnologies Inc.;   Second Xiangya Hospital of Central South University
Condition:   Crohn's Disease
Intervention:   Biological: Stem cells
Sponsor:   Kang Stem Biotech Co., Ltd.
Recruiting - verified September 2016
Condition:   Cerebral Palsy
Interventions:   Biological: Autologous Stem Cells;   Other: Saline Infusion (Placebo)
Sponsors:   The University of Texas Health Science Center, Houston;   Cord Blood Registry, Inc.;   Let's Cure CP Foundation;   Mission Connect, a program of TIRR Foundation
Active, not recruiting - verified June 2017
Condition:   Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor
Intervention:   Other: Cord Blood Transplantation
Sponsor:   Assistance Publique - Hôpitaux de Paris
Conditions:   Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions:   Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
Sponsor:   University of Pittsburgh
Recruiting - verified March 2017
Conditions:   EBV;   CMV;   Adenovirus
Interventions:   Drug: CTL for CMV seropositive donors;   Drug: CTL for CMV naïve donors
Sponsor:   Catherine Bollard
Recruiting - verified May 2017
Conditions:   Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions:   Other: Treg-enriched infusion;   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Miltenyi Biotec GmbH;   Prometheus Laboratories;   National Cancer Institute (NCI)
Recruiting - verified July 2017
Conditions:   Single Umbilical Cord Blood Transplantation;   Non-myeloablative Conditioning;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia
Intervention:   Drug: HSC835
Sponsor:   Novartis Pharmaceuticals
Completed - verified July 2017